Abstract: Objective To compare the efficacy and safety of Stronger Neo-Minophagen C (SNMC) in the treatment of chronic
hepatitis B. Methods We searched MEDLINE, EMBASE, CBM, and CNKI up to December, 2012 to identify randomized
controlled trials (RCTs) comparing Stronger Neo-Minophagen C plus other therapy versus others therapy for chronic hepatitis
B. Two reviewers independently assessed the risk of bias and extracted data from the included RCTs according to the Cochrane
Reviewer’s Handbook 5.1.0. Meta-analyses were performed using RevMan 5.1 software. Results Thirty-one trials involving
2753 patients were included in the analysis. The results of meta-analyses showed that SNMC improved hepatic functions of the
patients by reducing ALT (MD=-31.63，95% CI：-51.57，-11.70), AST (MD=-18.70, 95% CI:-25.10, -12.30), TBIL (MD=-12.17, 95%
CI: -17.63,-6.71), HA (MD=-94.89, 95% CI: -125.19, -64.60), LN (MD=-40.08, 95% CI: -52.38,-27.78), IV-C (MD=-50.61, 95%
CI:-63.40, -37.81), PC-III (MD=-49.71, 95% CI: -71.72, -27.69) as compared with the control group. The seroconversion rate of
HBeAg (OR=2.23, 95% CI: 1.70, 2.94), HBV-DNA (OR=2.20, 95% CI: 1.70, 2.84), HBsAg (OR=2.25, 95% CI: 1.24 , 4.07), total
response rate (OR=4.37, 95% CI: 2.62, 7.28), and ALT normalization rate (OR=3.77, 95% CI: 2.46, 5.79) were all significantly
higher in the combined therapy group than in the control group. Conclusion SNMC plus other therapy is more effective than
other therapy alone in improving the hepatic function and hepatic fibrosis and increasing hepatic seroconversion rate in
patients with chronic hepatitis B without causing serious adverse events. But considering the low quality of the included
studies, the results should be interpreted with caution and awaits further confirmation by high-quality, large-scale RCTs.